MarketWatch
These fintech stocks are loved by analysts and could bounce back in a big way
📊
AI Sentiment
Positive
7/10
- Home
- HQY
as of 03-06-2026 3:53pm EST
$78.02
$1.94
-2.42%
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | DRAPER |
| Market Cap: | 7.9B | IPO Year: | 2014 |
| Target Price: | $116.53 | AVG Volume (30 days): | 892.4K |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.88 | EPS Growth: | 70.31 |
| 52 Week Low/High: | $72.76 - $116.65 | Next Earning Date: | 05-11-2026 |
| Revenue: | $229,525,000 | Revenue Growth: | 28.68% |
| Revenue Growth (this year): | 10.44% | Revenue Growth (next year): | 7.47% |
| P/E Ratio: | 42.53 | Index: | N/A |
| Free Cash Flow: | 337.8M | FCF Growth: | +21.86% |
AI-Powered HQY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.14%
74.14%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of HealthEquity Inc. (HQY)
Ladd Delano
Sell
EVP, General Counsel
HQY Dec 19, 2025
Avg Cost/Share
$94.72
Shares
1,500
Total Value
$142,080.00
Owned After
73,979
SEC Form 4
Rosner Elimelech
Sell
EVP, CHIEF TECHNOLOGY OFFICER
HQY Dec 18, 2025
Avg Cost/Share
$95.45
Shares
10,959
Total Value
$1,046,090.25
Owned After
45,742
SEC Form 4
Wellborn Gayle Furgurson
Sell
Director
HQY Dec 12, 2025
Avg Cost/Share
$98.03
Shares
4,339
Total Value
$425,330.91
Owned After
19,733
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ladd Delano | HQY | EVP, General Counsel | Dec 19, 2025 | Sell | $94.72 | 1,500 | $142,080.00 | 73,979 | |
| Rosner Elimelech | HQY | EVP, CHIEF TECHNOLOGY OFFICER | Dec 18, 2025 | Sell | $95.45 | 10,959 | $1,046,090.25 | 45,742 | |
| Wellborn Gayle Furgurson | HQY | Director | Dec 12, 2025 | Sell | $98.03 | 4,339 | $425,330.91 | 19,733 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 17, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 17, 2026 · 100% conf.
AI Prediction SELL
1D
-3.29%
$71.91
5D
-5.46%
$70.30
20D
-6.71%
$69.37
Price: $74.36 Prob +5D: 0% AUC: 1.000
0001428336-26-000005
hqy-202602170001428336false00014283362026-02-172026-02-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 17, 2026
HEALTHEQUITY, INC.
Delaware 001-3656852-2383166
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number)
15 West Scenic Pointe Drive Suite 100 Draper, Utah 84020 (801) 727-1000
(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On February 17, 2026, HealthEquity, Inc. issued a press release attached as Exhibit 99.1 to this current report on Form 8-K. The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit No.Description 99.1Press release issued by HealthEquity, Inc. dated February 17, 2026
104Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTHEQUITY, INC.
Date: February 17, 2026By:/s/ James Lucania Name:James Lucania Title:Executive Vice President and Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Dec 3, 2025
2025
Q3
Q3 2025 Earnings
8-KDec 3, 2025
0001428336-25-000035
hqy-202512030001428336false00014283362025-12-032025-12-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 3, 2025
HEALTHEQUITY, INC.
Delaware 001-3656852-2383166
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number)
15 West Scenic Pointe Drive Suite 100 Draper, Utah 84020 (801) 727-1000
(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On December 3, 2025, HealthEquity, Inc. issued a press release attached as Exhibit 99.1 to this current report on Form 8-K. The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit No.Description 99.1Press release issued by HealthEquity, Inc. dated December 3, 2025, announcing financial results for its fiscal quarter ended October 31, 2025.
104Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTHEQUITY, INC.
Date: December 3, 2025By:/s/ James Lucania Name:James Lucania Title:Executive Vice President and Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Sep 2, 2025
2025
Q2
Q2 2025 Earnings
8-KSep 2, 2025
0001428336-25-000028
hqy-202509020001428336false00014283362025-09-022025-09-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
September 2, 2025
HEALTHEQUITY, INC.
Delaware 001-3656852-2383166
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number)
15 West Scenic Pointe Drive Suite 100 Draper, Utah 84020 (801) 727-1000
(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On September 2, 2025, HealthEquity, Inc. issued a press release attached as Exhibit 99.1 to this current report on Form 8-K. The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits (d) Exhibits
Exhibit No.Description 99.1Press release issued by HealthEquity, Inc. dated September 2, 2025, announcing financial results for its fiscal quarter ended July 31, 2025.
104Cover Page Interactive Data File (formatted in Inline XBRL)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTHEQUITY, INC.
Date: September 2, 2025By:/s/ James Lucania Name:James Lucania Title:Executive Vice President and Chief Financial Officer
Latest HealthEquity Inc. News
HQY Breaking Stock News: Dive into HQY Ticker-Specific Updates for Smart Investing
Compare HQY vs Leading Stocks
See how HQY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HQY HealthEquity Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.